Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis

Psychological Medicine

Volumn 44, Issue 1, 2014, Pages 37-50

  Pelayo Teran J M ^a,b   Diaz, F J ^c   Perez Iglesias R ^a,b   Suarez Pinilla P ^a,b   Tabares Seisdedos R ^b,d   De Leon J ^e   Crespo Facorro, B ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VALENCIA   (Spain)

^e EASTERN STATE HOSPITAL   (United States)

Author keywords

Antipsychotic; first episode psychosis; schizophrenia; treatment outcome; treatment trajectories

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BAYES THEOREM; CANNABIS SMOKING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PROGNOSIS; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL MODEL; PSYCHOLOGY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEX DIFFERENCE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BAYES THEOREM; BENZODIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; MODELS, PSYCHOLOGICAL; PROGNOSIS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84889797704     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713000330     Document Type: Article

References (38)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Archives of General Psychiatry 60, 1228-1235. (Pubitemid 37494076)
2. Andreasen NC (1983a). Scale for the Assessment of Negative Symptoms (SANS). University of Iowa: Iowa City.
3. Andreasen NC (1983b). Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa: Iowa City.
4. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P (1995). A longitudinal study of symptom dimensions in schizophrenia: prediction and patterns of change. Archives of General Psychiatry 52, 352-360.
5. Bobes J, Arango C, Garcia-Garcia M, Rejas J (2010). Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. Journal of Clinical Psychiatry 71, 280-286.
6. Buhler B, Hambrecht M, Loffler W, an der Heiden W, Hafner H (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 54, 243-251. (Pubitemid 34304217)
7. Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ (2011). The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychological Medicine 41, 1291-1300.
8. Caseiro O, Perez-Iglesias R, Mata I, Martinez-Garcia O, Pelayo-Teran JM, Tabares-Seisdedos R, Ortiz-Garcia de la Foz V, Vazquez-Barquero JL, Crespo-Facorro B (2012). Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study. Journal of Psychiatric Research 46, 1099-1105.
9. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 2063-2065. (Pubitemid 39619650)
10. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Pardo-Garcia G, Vazquez-Barquero JL (2007). Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research 41, 659-666. (Pubitemid 46509645)
11. Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, Martinez-Garcia O, Llorca J, Luis Vazquez-Barquero J (2006). A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. Journal of Clinical Psychiatry 67, 1511-1521. (Pubitemid 44787432)
12. Cuesta MJ, Peralta V (1995). Are positive and negative symptoms relevant to cross-sectional diagnosis of schizophrenic and schizoaffective patients Comprehensive Psychiatry 36, 353-361.
13. Czobor P, Bitter I, Volavka J (1991). Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: A study of their correlation and redundancy. Psychiatry Research 36, 129-139.
14. Diaz I, Pelayo-Teran JM, Perez-Iglesias R, Mata I, Tabares-Seisdedos R, Suarez-Pinilla P, Vazquez-Barquero JL, Crespo-Facorro B (2012). Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. Psychiatry Research. Published online 14 November 2012. doi:10.1016/j.psychres.2012.10.011.
15. Emsley R, Rabinowitz J, Medori R (2006). Time course for antipsychotic treatment response in first-episode schizophrenia. American Journal of Psychiatry 163, 743-745. (Pubitemid 44464590)
16. Geddes J, Freemantle N, Harrison P, Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321, 1371-1376.
17. Grube BS, Bilder RM, Goldman RS (1998). Meta-analysis of symptom factors in schizophrenia. Schizophrenia Research 31, 113-120. (Pubitemid 28307951)
18. Harvey PD, Koren D, Reichenberg A, Bowie CR (2006). Negative symptoms and cognitive deficits: what is the nature of their relationship Schizophrenia Bulletin 32, 250-258.
19. Jones BL, Nagin DS, Roeder K (2001). A SAS procedure based on mixture models for estimating developmental trajectories. Sociological Methods and Research 29, 374-393.
20. Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, Stroup TS; CATIE Investigators (2011). Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophrenia Research 132, 177-182.
21. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biological Psychiatry 57, 1543-1549. (Pubitemid 40805384)
22. Levine SZ, Leucht S (2010). Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biological Psychiatry 68, 86-92.
23. Levine SZ, Leucht S (2012). Delayed-and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. European Neuropsychopharmacology. Published online 14 April 2012. doi:10.1016/j. euroneuro.2012.03.001.
24. Levine SZ, Lurie I, Kohn R.Levav I (2011). Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophrenia Research 126, 184-191.
25. Levine SZ, Rabinowitz J (2010). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624-632.
26. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H (2010). Treatment response trajectories and their antecedents in recent-onset psychosis: A 2-year prospective study. Journal of Clinical Psychopharmacology 30, 446-449.
27. Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H (2012). Treatment response trajectories and antipsychotic medications: examination of up to18 months of treatment in the CATIE chronic schizophrenia trial. Schizophrenia Research 137, 141-146.
28. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 160, 1396-1404. (Pubitemid 41070913)
29. Marques TR, Arenovich T, Agid O, Sajeev G, Muthéen B, Chen L, Kinon BJ, Kapur S (2011). The different trajectories of antipsychotic response: Antipsychotics versus placebo. Psychological Medicine 41, 1481-1488.
30. Muthén B, Brown CH, Masyn K, Jo B, Khoo ST, Yang CC, Wang CP, Kellam SG, Carlin JB, Liao J (2002). General growth mixture modeling for randomized preventive interventions. Biostatistics 3, 459-475.
31. Muthén LK, Muthén BO (2007). Mplus: Statistical Analysis with Latent Variables: User's Guide, 5th edn. Muthén & Muthén: Los Angeles.
32. Overall JE, Gorham DR (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799-812.
33. Pelayo-Terán JM, Perez-Iglesias R, Ramírez-Bonilla M, González-Blanch C, Martínez-García O, Pardo-García G, Rodríguez-Sánchez JM, Roiz-Santiáñez R, Tordesillas-Gutiérrez D, Mata I, Vázquez-Barquero JL, Crespo-Facorro B (2008). Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Intervention in Psychiatry 2, 178-187.
34. Perkins DO, Gu H, Boteva K, Lieberman JA (2005). Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. American Journal of Psychiatry 162, 1785-1804. (Pubitemid 41428609)
35. Pini S, de Queiroz V, Dell'Osso L, Abelli M, Mastrocinque C, Saettoni M, Catena M, Cassano GB (2004). Cross-sectional similarities and differences between schizophrenia, schizoaffective disorder and mania or mixed mania with mood-incongruent psychotic features. European Psychiatry 19, 8-14. (Pubitemid 38210423)
36. Rabany L, Weiser M, Werbeloff N, Levkovitz Y (2011). Assessment of negative symptoms and depression in schizophrenia: revision of the SANS and how it relates to the PANSS and CDSS. Schizophrenia Research 126, 226-230.
37. Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Klingberg S, Gastpar M, Musil R, Möller HJ, Riedel M (2012). Response trajectories in "real-world" naturalistically treated schizophrenia patients. Schizophrenia Research 139, 218-224.
38. Stauffer V, Case M, Kollack-Walker S, Ascher-Svanum H, Ball T, Kapur S, Kinon BJ (2011). Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophrenia Research 130, 11-19.